Orion Oyj Class B ORNBV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- €102.70
- Day Range
- €102.10–103.40
- 52-Week Range
- €58.90–104.00
- Bid/Ask
- €102.90 / €103.00
- Shares Outstanding
- 140.24M
- Market Cap
- €14.44B
- Volume/Avg
- 111,333 / 155,625
Key Statistics
- Price/Earnings (Normalized)
- 21.46
- Price/Sales
- 6.66
- Dividend Yield (Trailing)
- 1.75%
- Dividend Yield (Forward)
- 1.75%
- Dividend Payment Schedule
- Apr, Oct
- Total Yield
- 1.75%
Company Profile
Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. The company mainly serves Finland but also has a presence in other European countries, North America and other countries.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 4,174
- Website
- https://www.orion.fi
Valuation
Metric | ORNBV |
|---|---|
Price/Earnings (Normalized) | 21.46 |
Price/Book Value | 10.34 |
Price/Sales | 6.66 |
Price/Cash Flow | 18.87 |
Price/Earnings
ORNBV
Financial Strength
Metric | ORNBV |
|---|---|
Quick Ratio | 1.61 |
Current Ratio | 2.72 |
Interest Coverage | 285.97 |
Quick Ratio
ORNBV
Profitability
Metric | ORNBV |
|---|---|
Return on Assets (Normalized) | 33.80% |
Return on Equity (Normalized) | 54.05% |
Return on Invested Capital (Normalized) | 45.28% |
Return on Assets
ORNBV
Drug Manufacturers - General Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Eli Lilly and Co LLY | LOCK|%M@R%m? | LOCK|Q$b | $1T | |||
| Johnson & Johnson JNJ | LOCK|fxGXtF | LOCK|@h? | $688B | |||
| AbbVie Inc ABBV | LOCK|h@Q<Zwl | LOCK|%G@ | $521B | |||
| Roche Holding AG ADR RHHBY | LOCK|&@^!gFPs | LOCK|%? | $387B | |||
| Merck & Co Inc MRK | LOCK|@!#dm% | LOCK|kq | $364B | |||
| Novartis AG ADR NVS | LOCK|R<%?bXD | LOCK|GN | $303B | |||
| AstraZeneca PLC AZN | LOCK|<@c>lz&< | LOCK|T#G | $287B | |||
| Amgen Inc AMGN | LOCK|lyL!jkj | LOCK|L!X | $252B | |||
| Gilead Sciences Inc GILD | LOCK|Z?q>pY | LOCK|@W@ | $208B | |||
| Novo Nordisk AS ADR NVO | LOCK|bp?W@$j | LOCK|M&h | $181B |
United States